About the 3rd Annual IOBDLI Forum

Taking place on the first day of ASCO, the 3rd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.
Plenary Sessions will include:
​
  • Industry Roundtable: “The Changing Landscape of Regulation, Reimbursement & Pricing Under the New Administration"
  • Current Trends in Pharma-Biotech Deal Making
  • New Approaches to IO & Combination Therapies
  • Latest Perspectives on Cell & Gene Therapies
  • Technology & Innovation
  • New Session: China-US DealMaking with overview by Helen Chen, Managing Director and Head of China Life Sciences, L.E.K. Consulting
  • Investor Roundtable
​Confirmed Keynotes Include:​
​
  • “Oncology within the Context of the Changing Reimbursement Landscape” by Roger Longman, CEO, Real Endpoints
  • ​​“Perspectives on Cell Therapies” by Samuele Butera, Global Cell & Gene Therapies Business Leader, Novartis Oncology
Confirmed Speakers Include:​​​
  • Aaron Foster, Vice President of Product Discovery, Bellicum Pharmaceuticals, Inc. 
  • Axel Hoos, SVP, TA Head, Oncology R&D, GSK
  • Bard Geesaman, Managing Director, MPM Capital
  • Bibhash Mukhopadhyay, Principal, New Enterprise Associates
  • Boris Peaker, Managing Partner, Biotechnology Equity Research, Cowen and Company
  • Brad Loncar, CEO, Loncar Investments
  • Chris DeRespino, Director, Business Development, Amgen, Inc.
  • David Malek, Chief Business Officer, BioLineRx Ltd.
  • Debra Bowes, EVP, Business and Strategic Development, MaxCyte, Inc.
  • Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center
  • Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo
  • Gary Sclar, Vice President, Dana-Farber Innovations, Dana-Farber Cancer Institute
  • Gregory Frost, CEO and Chairman, F1BioVentures
  • Gregory Naeve, Head External R&D Innovation, ImmunoOncology & Rinat Labs, San Francisco, Pfizer, Inc.
  • Guillaume Vignon, Head of Immuno-Oncology Licensing & Business Development , EMD Serono, Inc.
  • Helen Chen, Managing Director and Head of China Life Sciences, L.E.K. Consulting Limited
  • Helen Tayton-Martin, Chief Business Officer, Adaptimmune Therapeutics
  • Hongbo Lu, Partner, Lilly Asian Venture
  • Howard Fingert, Senior Medical Director for Clinical Intelligence, Takeda Pharmaceuticals
  • Ian Woo, Managing Director, Healthcare Banking, Lazard
  • James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center
  • Ji Li, Global Head of Business Development, BeiGene
  • John Beadle, CEO, PsiOxus Therapeutics Ltd.
  • Joseph Sum, Director of Research, EcoR1 Capital, LLC
  • Juergen Gamer, VP Business Development, Apogenix AG
  • Julie Locklear, Vice President & Head Health Economics & Outcomes Research, EMD Serono, Inc.
  • Kuldeep Neote, Senior Director, New Ventures, J&J Innovation Centre-Boston
  • Lee Greenberger, SVP and CSO, The Leukemia & Lymphoma Society
  • Lindy  Du